Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 13/20 | 0.47 |
| ▸ | VHL | P40337 | 4/20 | 0.42 |
| ▸ | ELOC | Q15369 | 3/20 | 0.42 |
| ▸ | ELOB | Q15370 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20425310 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL31040654 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL20425493 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL18551323 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL3369964 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL13318867 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL25339541 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL806127 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL30178517 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB | |
| SCHEMBL29091282 | 1.00 | ATM (0.49) | ATMELANEVHLELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361958-B2 | Oximyl HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361958-B2 | Oximyl HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-7635683-B2 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635683-B2 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7605126-B2 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605126-B2 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090098085-A1 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090098085-A1 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20080317712-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008021956-A2 | ACYLAMINOHETEROARYL HEPATITIS C VIRUS PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080039470-A1 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039470-A1 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, CTSC | ATM 3646/4885ELANE 145/4885VHL 3062/4885 |
| US-20080039470-A1 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ATG4A, CYP4A22, AADAC | ATM 4096/4885ELANE 311/4885VHL 2345/4885 |
| US-20080317712-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | PREP, DNPEP, CTSC | ATM 4374/4885ELANE 277/4885VHL 2564/4885 |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | VIP, CTSC, PREP | ATM 4706/4885ELANE 396/4885VHL 2532/4885 |
| US-20090098085-A1 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | ATM 3561/4885ELANE 181/4885VHL 3115/4885 |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | ATM 3490/4885ELANE 469/4885VHL 2900/4885 |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | ATM 4387/4885ELANE 355/4885VHL 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.